Blocking CXCR4+ CD4+ T cells reprograms Treg-mediated immunosuppression via modulating the Rho-GTPase/NF-κB pathway

ABSTRACT: Clinical trials have demonstrated that CXCR4 antagonists enhance the efficacy of immunotherapy in cancers by reducing regulatory T (Treg) cells, elucidating how certain mechanisms of CXCR4 in affecting Treg cells are essential for developing immunotherapeutic strategies.

ORGANISM(S): Homo Sapiens

SUBMITTER: Canhui Cao  

PROVIDER: PXD058262 | iProX | Mon Nov 25 00:00:00 GMT 2024

REPOSITORIES: iProX